# Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation

> **NCT02535286** · PHASE1 · COMPLETED · sponsor: **TG Therapeutics, Inc.** · enrollment: 27 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Richter Syndrome

## Interventions

- **DRUG:** Umbralisib
- **BIOLOGICAL:** ublituximab
- **BIOLOGICAL:** TG-1501

## Key facts

- **NCT ID:** NCT02535286
- **Lead sponsor:** TG Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-18
- **Primary completion:** 2021-11-04
- **Final completion:** 2021-11-04
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2022-10-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02535286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02535286, "Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02535286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*